Also known as Glivec (Gleevec; Novartis) Imatinib is a small-molecule inhibitor acting as a competitive antagonist of adenosine triphosphate (ATP) binding to Abl-PK, which is applied successfully in human cancer therapy [40]. Here, ABL1 is linked to cancer.